IMR Press / FBL / Volume 17 / Issue 1 / DOI: 10.2741/3919

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Epigenetic mechanisms of plant-derived anticancer drugs
Show Less
1 Division Experimental Tumorpathology, Institute for Pathology, University Erlangen-Nuremberg, Erlangen, Germany
2 Biology Department, American University of Beirut, Beirut, Lebanon
3 Biology Department, United Arab Emirates (UAE) University, AlAin, UAE
Academic Editor:Hala Gali-Muhtasib
Front. Biosci. (Landmark Ed) 2012, 17(1), 129–173;
Published: 1 January 2012
(This article belongs to the Special Issue New emerging anticancer lead compounds from plants)

Epigenetic mechanisms are essential for normal development and maintenance of adult life. Disruption of epigenetic processes results in deregulated gene expression and leads to life-threatening diseases, in particular, cancer. Global epigenetic alterations are a hallmark of cancer. Cancer epigenetics revealed the deregulation of all components of the epigenetic machinery including DNA methylation, histone modifications, chromatin structure, and non-coding RNAs. Drugs targeting epigenetic processes, or "epi-drugs", are at the forefront of drug discovery, and plant-derived compounds have shown promise. Most of the plant-derived anticancer drugs that work through epigenetic mechanisms are polyphenols; the others are alkaloids, organosulfur compounds, and terpenoids. This review focuses on the epigenetic machinery and its basis for cancer therapy, highlights plant-derived anticancer drugs with epigenetic mechanisms of action, and discusses their potential use in epigenetic therapy.

Anticancer drug
DNA methylation
Histone modification
Combination treatment
Epigenetic drug dosage
Back to top